Novo Nordisk secures EU nod for higher Wegovy dose amid intensifying GLP-1 competition
EU approves 7.2 mg Wegovy for obesity. Explore what this means for efficacy, competition and reimbursement across Europe.
Biofrontera targets U.S. label expansion for Ameluz in trunk and extremities
Phase 1 PK data bring Ameluz closer to broader FDA review. Explore the regulatory stakes and market impact in actinic keratosis.
What AstraZeneca’s KALOS and LOGOS data reveal about triple inhaler therapy in asthma
AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.
Can Alto Neuroscience’s ALTO-101 finally move the needle on cognitive impairment in schizophrenia?
Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in CIAS. Discover what the upcoming data could mean for precision psychiatry.
Is Novartis Pharma AG positioned to convert accelerated approval for Vanrafia in 2026?
Novartis reports Phase III ALIGN data for Vanrafia in IgA nephropathy. Discover what this means for full approval in 2026.
Medtronic secures FDA clearance for Stealth AXiS surgical system in spine robotics
Medtronic wins FDA clearance for Stealth AXiS in spine robotics. Explore what this integrated platform means for workflow, data, and adoption.
What Kailera Therapeutics and Hengrui Pharma’s Phase 2 ribupatide results reveal about oral GLP-1 viability
Can oral ribupatide reshape obesity treatment economics and adoption? Explore what Phase 2 data mean for GLP-1 pill strategies.
Can Regeneron Pharmaceuticals redefine allergy treatment with Phase 3 allergen-blocking antibodies and Dupilumab expansion
Find out how Regeneron Pharmaceuticals’ AAAAI 2026 data could reshape allergy treatment strategies and regulatory expectations.
What Kainova Therapeutics’ latest financing reveals about the future of CCR8-targeted cancer therapies
Find out how Kainova Therapeutics’ $32M CAD funding could reshape GPCR-based immuno-oncology and inflammation drug development.
What Nicox SA’s NCX 470 presentations signal for nitric oxide–based eye therapies
Discover how Nicox SA’s NCX 470 Phase 3 data could reshape glaucoma treatment and regulatory strategy. Read the full analysis.